Search
Tranexamic acid
go.drugbank.com/drugs/DB00302ApprovedInvestigationalIt possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent.
Products: ZYEX-T, HEAMIC-T (Tranexamic Acid Injection 100mg/mL)Tyrosine
go.drugbank.com/drugs/DB00135ApprovedInvestigationalNutraceuticalTyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.
Factor XIII (human)
go.drugbank.com/drugs/DB12909ApprovedInvestigationalThis contributes to enhanced platelet and clot adhesion to injured tissue, thereby improving blood coagulation and maintenance of hemostasis [A18581]. … When activated by thrombin at the site of injury, the FXIII pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit.
Paliperidone
go.drugbank.com/drugs/DB01267ApprovedInvestigationalThe mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. … Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeEtoposide
go.drugbank.com/drugs/DB00773ApprovedInvestigationalAccumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. … Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding.
Synonyms: 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside), 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-oneBretylium
go.drugbank.com/drugs/DB01158ApprovedRecent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site. … The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels.
Netupitant
go.drugbank.com/drugs/DB09048ApprovedInvestigationalThe combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo. … Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy
Telithromycin
go.drugbank.com/drugs/DB00976ApprovedSimilar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. … It is used to treat mild to moderate respiratory infections.
Navepegritide
go.drugbank.com/drugs/DB17824ApprovedInvestigationalAchondroplasia, the most prevalent skeletal dysplasia, is caused by a gain-of-function variant in the fibroblast growth factor receptor 3 (FGFR3), which leads to overactive downstream signaling that inhibits … [L56058] Developed to address the clinical limitations of daily therapies, the pegylated nature of navepegritide allows for once-weekly dosing while providing sustained systemic exposure to CNP, which
Tilactase
go.drugbank.com/drugs/DB13761ApprovedInvestigationalIt is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal. … [A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338]